白细胞介素1基因位点变异与心包炎关联研究
该研究通过全基因组关联荟萃分析,在4894例心包炎患者中鉴定出白细胞介素1基因位点(2q14)两个独立常见变异与心包炎相关,先导变异rs12992780对复发性心包炎OR更小,提示IL-1通路在发病中的作用,可能助力靶向治疗开发。
要点
- 心包炎与IL1基因位点两个独立变异相关,先导变异rs12992780(T)OR=0.83。
- rs7575402与调控IL-1产生的转录因子结合位点CpG甲基化相关。
核心结论
- 心包炎与白细胞介素1基因位点两个独立序列变异相关,该发现可能促进IL-1阻断药物更靶向和个体化治疗心包炎的开发。
研究设计与样本
- 研究为全基因组关联研究(GWAS)的荟萃分析,纳入来自5个国家(冰岛、丹麦、英国、美国、芬兰)的数据,共4894例心包炎个体(平均年龄51.4岁,2734例男性,排除FinnGen队列),并整合转录组和蛋白质组数据。
主要发现
- 先导变异rs12992780(T)效应等位基因频率31%-40%,OR=0.83(95%CI 0.79-0.87,P=6.67×10^-16),位于IL1B下游。
- 次要变异rs7575402(A或T)效应等位基因频率45%-55%,校正OR=0.89(95%CI 0.85-0.93,校正P=9.6×10^-8)。
- rs7575402与CpG甲基化相关,该甲基化区域重叠PU.1(SPI1编码)、STAT1、STAT3和CCAAT/增强子结合蛋白β(CEBPB编码)四个调控IL-1产生的转录因子结合位点。
临床怎么用
- 该遗传关联证据支持IL-1通路在心包炎发病中的作用,提示IL-1阻断药物可能用于心包炎治疗,尤其需关注复发性心包炎患者。
- 临床可关注IL1基因位点变异信息,未来或有助于筛选从IL-1靶向治疗中获益的人群。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood. OBJECTIVE: To use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis. DESIGN, SETTING, AND PARTICIPANTS: This was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023. EXPOSURE: Genotype. MAIN OUTCOMES AND MEASURES: Pericarditis. RESULTS: In this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10-16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10-8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB). CONCLUSIONS AND RELEVANCE: This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.
引用
- Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, et al. Variants at the Interleukin 1 Gene Locus and Pericarditis. JAMA Cardiol. 2024. PMID: 38150231. doi:10.1001/jamacardio.2023.4820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。